PharmacyPharmacokineticsPharmacologyRenal PharmacokineticsRenal PharmacotherapyTransplant PharmacotherapyLiver Transplant PharmacotherapyLiver TransplantationPharmacokinetics In Renal ImpairmentRenal DiseaseTransplant PharmacokineticsTransplant RejectionCyclosporine DosingCyclosporine PharmacokineticsLiver Transplant RejectionMaintenance Immunosuppression PharmacokineticsPharmacokinetics In Liver TransplantationPharmacokinetics In Transplantation
a macrolide antibiotic. is a powerful immuno- suppressant which is approximately 100 times more potent than cyclosporine (CyA).The first clinical experience with this agent was attained in patients with refractory hepatic rejection and complications of Cy A therapy.l.2Initial experience suggested that FK 506 was surprisingly effective in reversing rejection in these patients.In the first patients.the combined nephrotoxicity of FK 506 and CyA was apparent.Serum creatinine (SCr) regularly increased and, at times, dramatically.3This was termed the "crossover nephrotoxicity" of FK 506 and Cy A. FK 506 has now been used for approximately 2 years at the University of Pittsburgh.We will update our experience with the changes in renal function after conversion from CyA to FK 506.
3
John J. Fung, Satoru Todo, A Jain et al. · PubMed · 1990 · 111 citations
The effects of FK 506 on renal function after liver transplantation.
J McCauley, John J. Fung, Ashokkumar Jain et al. · PubMed · 1990 · 67 citations · Full text
Medicine, Pharmacokinetics, Surgery +13
Thomas E. Starzl, Kareem Abu‐Elmagd, Andreas G. Tzakis et al. · PubMed · 1991 · 58 citations · Full text